Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance

Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.

Authors

Institutions

Publication Details

Journal
Arthritis Research & Therapy
Published
2026-09-29
DOI
https://doi.org/10.1186/s13075-026-03898-4
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance

Hongyu Jie, Yuqing Wang, Shixiong Cao, Yongkun Bai et al.
Arthritis Research & Therapy
Systemic Lupus Erythematosus Research
article

Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance

Hongyu Jie, Yuqing Wang, Shixiong Cao, Yongkun Bai, Xiaozhen Zhao, Haotian Zhou, Erwei Sun, Xiaolin Sun, Chuanhui Xu, Junyi Jiang, Xingyue Zeng, Wenjuan Zhang
article en

Abstract

Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.

Arthritis Research & Therapy
Nanyang Technological University (SG), Peking University (CN), Tan Tock Seng Hospital (SG), Third Affiliated Hospital of Southern Medical University (CN), Peking University People's Hospital (CN), Beijing Proteome Research Center (CN), Southern Medical University (CN)
Good health and well-being
Openalex Percentile: Top 11%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.